Table 3.
Monoamine receptor studies.
| Reference | Study design | Main findings | Comments |
|---|---|---|---|
| Mervaala et al. (157) | Noradrenaline challenge with alpha 2-antagonist atipamezole (0.1 mg/kg) in six healthy male volunteers | Reduced P3 amplitude without affecting MMN and Nd; improved digit span and word recognition performance | Small sample size; study did not report ERPs in response to standard stimuli |
| Schreiber et al. (158) | Double-blind, placebo-controlled crossover administration of ceruletide (0.5 and 2.5 mg) in 13 healthy volunteers | No effect on MMN; PN larger with ceruletide | Study did not report ERPs in response to standard stimuli |
| Kahkonen et al. (159) | Placebo-controlled haloperidol challenge (2 mg) in 12 healthy volunteers | MMN increased with haloperidol without affecting other ERP components | MEG measures were unaffected; study reported ERPs in response to standard stimuli |
| Pekkonen et al. (160) | Haloperidol challenge 2 mg in 12 healthy volunteers | No effect on MMN | Study reported ERPs in response to standard stimuli |
| Ahveninen et al. (161) | 5HT challenge using acute tryptophan depletion versus placebo control in 13 healthy volunteers | Delayed MMN latency | Study reported ERPs in response to standard stimuli |
| Umbricht et al. (131) | Single-blind, placebo-controlled psilocybin challenge (0.28 mg/kg) in 18 healthy volunteers and ketamine (0.9 mg/kg/h) in 20 healthy volunteers whilst performing a continuous performance task | Smaller MMN to frequency and duration deviants was correlated with stronger effects on the brief psychiatric rating scale during ketamine but not psilocybin | Study does not report MMN in the respective placebo conditions and did not report ERPs in response to standard stimuli |
| Leung et al. (162) | Double-blind, placebo-controlled crossover administration of bromocriptine (2.5 mg) or pergolide (0.1 mg) in 15 healthy volunteers | No effect on MMN, P1, N1, N2, and P3 | Study reported ERPs in response to standard stimuli |
| Korostenskaja et al. (163) | Double-blind, placebo-controlled crossover administration of methylphenidate challenge (40 mg) in 13 healthy volunteers | No effect on MMN or N1; P2 amplitude reduction with methylphenidate | Study reported ERPs in response to standard stimuli |
| Leung et al. (164) | Double-blind, placebo-controlled crossover design following tyrosine/phenylalanine and/or tyrosine depletion intervention in 16 healthy volunteers | No effects on ERPs | Study reported ERPs in response to standard stimuli |